hsa_circ_0081143

ncRNA information

ncRNA name

hsa_circ_0081143

Specific or universal ncRNAs

Specific ncRNAs

Class

Circular RNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

miR-646/CDK6

Cancer information

Cancer name

Gastric Cancer

Cancer site

Stomach

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Up

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Up

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

Our study indicated a novel regulatory loop that hsa_circ_0081143/miR-646/CDK6 in GC progression. These data suggested that hsa_circ_0081143 might act as a potential novel therapeutic strategy for GC treatment.

Tissue resource

human gastric cancer tissues and adjacent non-tumor tissues

human gastric cancer cell lines SGC7901

human gastric cancer cell lines MGC803

human gastric epithelial cell lines GES1

human gastric cisplatin-resistant cell lines SGC7901/DDP

human gastric cisplatin-resistant cell lines MGC803/DDP

Experiment

qPCR,Western blot,Luciferase reporter assay


Institute

First Affiliated Hospital of XinXiang Medical University

Biochemistry and Cell Biology of the Chinese Academy of Sciences

Keygen Biotechnology Co., Ltd

Country

China

Continent

Asia